Not Yet RecruitingPhase 1/2

Eculizumab for Prevention of Antibody-Mediated Rejection in ABO-Incompatible Living Donor Kidney Transplantation

China30 participantsStarted 2024-07

Plain-language summary

The aim of this study is to determine whether a single dose of eculizumab can effectively prevent antibody-mediated rejection in recipients undergoing living donor kidney transplantation with a different ABO blood group type than their donors

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. aged ≥ 18 years, male or female
✓. Suffering from end-stage renal disease and planning for ABO blood group incompatible living donor kidney transplantation
✓. Vaccinated against Neisseria meningitides (quadrivalent vaccine), Pneumococcus or H. influenzae at least two weeks prior to using eculizumab
✓. Be able to understand the informed consent form and willing to comply with the protocol

Exclusion criteria

✕. Previous splenectomy
✕. Any active bacterial or other infection
✕. Known or suspected hereditary complement deficiency
✕. Known hypersensitivity to the treatment drug or any of its excipients
✕. History of Neisseria meningitidis
✕. Any health condition that the investigator believes may interfere with the patient's participation, pose additional risks to the patient, or confound with the patient's assessment (e.g. severe cardiovascular or pulmonary disease)

What they're measuring

The incidence of AMR within 6 months after transplantation

Timeframe: 6 months after kidney transplant surgery

Trial details

NCT IDNCT06453135

SponsorTao Lin

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-07

Contact for this trial

Tao Lin, M.D.

18980602093 dr_taolin@163.com

View on ClinicalTrials.gov More Kidney Transplantation trials